TNF Pharmaceuticals (TNFA) Stock Price, News & Analysis

Company Overview

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Key Stats

• Today's Range: $5.15 to $6.95
• 50-Day Range: $3.30 to $15.44
• 52-Week Range: $3.24 to $195.00
• Volume: 8.14 million shs
• Average Volume: 3.51 million shs
• Market Capitalization: $10.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

TNF Pharmaceuticals Stock Analysis - MarketRank™

TNF Pharmaceuticals scored higher than 3% of companies evaluated by MarketBeat, and ranked 940th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for TNF Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of TNF Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TNF Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

TNF Pharmaceuticals has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.31% of the float of TNF Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

TNF Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TNF Pharmaceuticals has recently increased by 443.28%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TNF Pharmaceuticals does not currently pay a dividend.

Dividend Growth

TNF Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

18.31% of the float of TNF Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

TNF Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TNF Pharmaceuticals has recently increased by 443.28%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Sentiment

TNF Pharmaceuticals has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for TNF Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

Only 5 people have searched for TNFA on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

3 people have added TNF Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TNF Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.45% of the stock of TNF Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 9.64% of the stock of TNF Pharmaceuticals is held by institutions.

TNFA Stock Analysis - Frequently Asked Questions

How have TNFA shares performed this year?

TNF Pharmaceuticals' stock was trading at $115.00 at the start of the year. Since then, TNFA shares have decreased by 95.0% and is now trading at $5.75.

How were TNF Pharmaceuticals' earnings last quarter?

TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) posted its quarterly earnings data on Tuesday, August, 19th. The company reported ($18.00) EPS for the quarter.

When did TNF Pharmaceuticals' stock split?

TNF Pharmaceuticals shares reverse split on the morning of Tuesday, September 2nd 2025.The 1-100 reverse split was announced on Thursday, August 28th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of TNF Pharmaceuticals?

Shares of TNFA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TNF Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TNF Pharmaceuticals investors own include Amprius Technologies (AMPX), Archrock (AROC), Axon Enterprise (AXON), PACCAR (PCAR), Bitfarms (BITF), Bitfarms (BFARF) and BigBear.ai (BBAI).

Company Calendar

• Last Earnings: 8/19/2025
• Today: 10/05/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TNFA
• Previous Symbol: NASDAQ:MYMD
• CIK: 1321834
• Web: tnfpharma.com
• Phone: (856) 848-8698
• Fax: 856-848-0269
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($231.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.36 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -69.21%
• Return on Assets: -33.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.93
• Quick Ratio: 0.93

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $286.76 per share
• Price / Book: 0.02

Miscellaneous

• Outstanding Shares: 1,847,000
• Free Float: 1,839,000
• Market Cap: $10.62 million
• Optionable: N/A
• Beta: 2.04